Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
Multiple tranches Oct 1–2 at $77.12–$81.90 per share blended ~$79.65 avg; spot $74.44 (−6.5% since buy). Part of Sept–Oct LEN accumulation campaign totaling $245M+. No 10b5-1 plan indicated.
Bought at $7.51; spot $7.55 (+0.5%). L1 Capital (Australian hedge fund) adding to Anteris Technologies position — structural heart device company (DurAVR TAVR platform).
Oct 1: 228,334 shares at $3.53; Oct 2: 16,575 shares at $3.88. Spot $4.10 (+15.5% since buy). Activist 10% owner via BML Capital Management continuing to accumulate depressed healthcare device name.
AIThe day in insider buying
SEC Form 4 Insider Scan — October 6, 2026
Scanned the last 24 hours of EDGAR Form 4 filings. 5 qualifying buys (≥ $250K, transaction type P) totalling $219.1M.
Headline Filings
LEN — Berkshire Hathaway Inc / Warren E. Buffett (10% Owner) bought 2,415,837 shares ≈ $192.6M at ~$79.65 avg; now $74.44 (−6.5% since buy). (filing) Multiple tranches over Oct 1–2; Berkshire's continued LEN accumulation now totals $245M+ since late September.
GME — Ryan Cohen (President, CEO & Chairman) bought 700,000 shares ≈ $17.1M at $24.41 avg; now $25.24 (+3.4% since buy). (filing) 4th consecutive open-market purchase since Sept 10; no 10b5-1 plan. Post-transaction direct ownership: 41.6M shares.
AVR — L1 Capital Pty Ltd (Large Shareholder) bought 648,455 shares ≈ $4.9M at $7.51; now $7.55 (+0.5% since buy). (filing) Australian hedge fund L1 Capital building a position in Anteris Technologies (structural heart / TAVR).
ACCV — Michael Rubiera (CEO) bought 203,200 shares ≈ $3.7M at $18.00; now $16.46 (−8.6% since buy). (filing) IPO directed share program; cluster buy — 4+ directors and executives purchased on the same day.
OM — Braden M. Leonard (10% Owner, BML Investment Partners) bought 244,909 shares ≈ $870K at ~$3.55 avg; now $4.10 (+15.5% since buy). (filing) Activist 10% owner continuing to accumulate Outset Medical at depressed prices.
Notes
Dominant theme — Homebuilders: Berkshire's $192.6M LEN tranche dominates the scan. Despite the stock now sitting ~6.5% below their blended entry (~$79.65), Buffett is methodically adding to what appears to be a concentrated homebuilder thesis heading into 2027.
GME momentum: Ryan Cohen has made 4 open-market purchases totaling an estimated ~$63M since September 10 — all without a pre-planned 10b5-1 schedule. The stock is +3.4% above his most recent entry.
ACCV IPO watch: Accelevation Holdings is newly public (IPO Oct 1). CEO Rubiera purchased $3.7M in the directed share program alongside 4+ other executives — a strong cluster signal for the first trading week.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.